John Hamill - Mar 13, 2024 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
SrVP/CFO/Prin Fin & Acct Ofcr
Signature
/s/ John Hamill
Stock symbol
APRE
Transactions as of
Mar 13, 2024
Transactions value $
$7,363
Form type
4
Date filed
3/14/2024, 08:54 PM
Previous filing
Feb 27, 2023
Next filing
Mar 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Purchase $7.36K +1.01K +6.97% $7.29 15.5K Mar 13, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Tranche A Warrant Purchase +505 505 Mar 13, 2024 Common Stock 505 Direct F1, F2, F3
transaction APRE Tranche B Warrant Purchase +505 505 Mar 13, 2024 Common Stock 505 Direct F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price of the Tranche A Warrants is as follows: 505 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share.
F2 Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
F3 The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.
F4 The exercise price of the Tranche B Warrants is as follows: 505 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share.
F5 Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
F6 The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.